Liver Cancer (LC) (Project-003)

摘要-肝癌研究 项目负责人：Scott Friedman，MD和Josep Llovet，MD 肝癌（LC）计划是一个综合性的多学科计划，包括所有方面， 从社区筛查到肝癌发生的基本机制， 肝细胞癌（HCC）和肝内胆管癌（ICC）。该计划的目标 目的是：1）阐明慢性肝脏或胆道疾病的基本机制， 纤维化急剧增加HCC和ICC的风险; 2）将这些基本进展转化为新的 HCC和ICC的诊断和分子分层的方法; 3）测试这些新的 干预措施，包括药物启动的早期临床概念验证试验，以及随后的关键性 随机研究。 从这个焦点发展的主题是：1）慢性肝脏炎症的基本机制 2）肝纤维化和HCC的分子和细胞基础; 2）新的模型和临床前 肝癌发病机制和治疗的研究; 3）创新的治疗临床前和临床策略， 肝癌（HCC和ICC）。该方案的重点包括：a）建立综合社区 致力于在服务不足的人群中筛查慢性肝病的外展计划，与 护理新诊断的肝病; B）在患者预防管理方面的独特临床专业知识 通过肝炎治疗和HCC的手术护理治疗慢性肝病; c）基础和转化 重新定义HCC和ICC的分子分类的研究计划; d）富有成效的HCC组织， 血清库，为西奈山的科学家和世界各地的调查人员提供了独特的一套， 基因组学、蛋白质组学和表观遗传学数据; e）HCC和ICC的稳健临床试验计划， 在美国参加HCC临床试验。该计划具有独特的定位，以实现其长期 我们的目标是在理解HCC和ICC机制方面取得突破性进展，并应用这些进展， 致力于开发和早期测试新的个性化疗法，这将改善 患有这些灾难性恶性肿瘤的患者 LC计划有24名成员，他们代表10个部门和6个研究所。截至2014年7月1日， 计划成员获得了3，124，363美元的NCI和其他同行评审的癌症相关直接支持。 自2011年以来，LC计划成员发布了220份报告，其中28.6%是计划内报告， 方案间8.2%。

ABSTRACT – LIVER CANCER (LC) RESEARCH PROGRAM Program Leaders: Scott Friedman, MD and Josep Llovet, MD The Liver Cancer (LC) Program is a comprehensive multidisciplinary program that incorporates all aspects of the disease from community screening to fundamental mechanisms of heptocarcinogenesis in both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The objectives of this program are to: 1) Elucidate fundamental mechanisms underlying the basis of how chronic liver or biliary disease and fibrosis precipitously increase the risk of HCC and ICC; 2) Translate these fundamental advances into novel approaches to the diagnosis and molecular stratification of HCC and ICC; 3) Test the efficacy of these novel interventions in investigator-initiated, early clinical proof-of concept trials and subsequently in pivotal randomized studies. The themes that have developed from this focus are: 1) Basic mechanisms of chronic hepatic inflammation that lead to HCC; 2) Molecular and cellular basis of hepatic fibrosis and HCC; 2) Novel models and pre-clinical studies of HCC pathogenesis and treatment; 3) Innovative therapeutic pre-clinical and clinical strategies for liver cancer (HCC and ICC). Highlights of the program include: a) Established comprehensive community outreach programs devoted to screening for chronic liver disease among underserved populations, linked to care for newly diagnosed liver disease; b) Unique clinical expertise in the preventive management of patients with chronic liver disease through hepatitis treatments and surgical care of HCC; c) A basic and translational research program that is redefining the molecular classification of HCC and ICC; d) A fruitful HCC tissue and serum bank that provides Mount Sinai scientists and investigators throughout the world with unique sets of genomic, proteomic and epigenetic data; e) A robust clinical trials program in HCC and ICC that has led the United States in enrollment in HCC clinical trials. The program is uniquely positioned to achieve its long-term goal to generate groundbreaking advances in understanding mechanisms of HCC and ICC, and to apply these towards the development and early testing of novel, personalized therapies that will improve the outlook for patients with these catastrophic malignancies The LC program has 24 members, and they represent 10 departments and 6 institutes. As of July 1, 2014, program members were awarded $3,124,363 in NCI and other peer-reviewed cancer-related direct support. Since 2011, LC program members published 220 reports, of which 28.6% were intra-programmatic and 8.2% inter-programmatic.